Healthcare Industry News: AngioDynamics
News Release - March 1, 2010
Delcath Systems Names Michael D. Dellario as Vice President, Global MarketingNEW YORK, March 1 (Healthcare Sales & Marketing Network) -- Delcath Systems, Inc. (Nasdaq:DCTH ), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has named Michael D. Dellario, 57, to the newly-created position of Vice President, Global Marketing, effective today. Mr. Dellario will report to Agustin Gago, EVP, Global Sales and Marketing.
"The new position of Vice President, Global Marketing is a critical component as we build our domestic and international commercialization team in anticipation of FDA approval and CE designation for the Delcath PHP Systemô," said Mr. Gago. "Michael's record of success in bringing innovative medical products to worldwide markets gives us confidence that he will have a significant impact on the commercialization of the Delcath PHP System as we continue to implement our plans in key European and Asian markets."
Mr. Dellario was most recently a marketing consultant for startup medical companies in the early stages of marketing development, providing marketing strategies and commercialization support. Prior to that, Mr. Dellario was Managing Director, Asian Operations at E-Z-EM/Bracco Inc., a medical equipment and software, devices and diagnostic pharmaceuticals company, from 2006 to 2008. There, he designed a focused marketing program and channel distribution plan that grew Asian business by 78%. Before that, he was Vice President of Marketing at Ekos Corp., Inc., an interventional devices and equipment startup focusing on therapeutic ultrasound.
From 1992 to 2005, Mr. Dellario held several marketing positions at AngioDynamics, Inc. Prior to that, he held sales and marketing positions for medical technology companies. Mr. Dellario received his MBA from Lidenwood University and his BS from St. Louis University, both in St. Louis, Missouri.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents. In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other forms of tumor metastases to the liver. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Source: Delcath Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.